24,424 results
Search Results
2. SERS Platform Based on Bimetallic Au-Ag Nanowires-Decorated Filter Paper for Rapid Detection of miR-196ain Lung Cancer Patients Serum.
- Author
-
Xia, Ji, Liu, Yifan, Ran, Menglin, Lu, Dan, Cao, Xiaowei, and Wang, Youwei
- Subjects
- *
SERS spectroscopy , *FILTER paper , *LUNG cancer , *CANCER patients , *SUCCINIC anhydride , *RAMAN scattering - Abstract
Detecting microRNA (miRNA) biomarkers expression is of great significance for the diagnosis and treatment of lung cancer. Surface-enhanced Raman scattering (SERS) has achieved microRNA sensing for the diagnosis of primary liver cancers. In this work, we developed a SERS technology for the rapid detection of lung cancers-related miRNA (miR-196a) using bimetallic Au-Ag nanowire (AgNW@AuNPs) substrates coupled with the target hairpin DNA. The finite-difference time-domain simulation proved that a large number of "hot spots" were generated between the AgNW and AuNPs, which resulted in a huge enhancement of the signal of Raman reporters. Filter paper treated by hexadecenyl succinic anhydride hydrophobic and modified with AgNWs@AuNPs was used as capturing substrate. The detection limits of miR-196a in PBS and serum were as low as 96.58 aM and 130 aM, respectively. Studies on nonspecific sequence and single-base mismatch of miRNA demonstrated that SERS-based platform was highly selective, excellent uniform, and reproducible. Finally, the platform was used to show that the miR-196a expression in the serum of lung cancer patients was much higher than that in healthy people. The detection results indicated that the SERS platform had potential applications in cancer diagnosis and might be a viable alternative to the conventional miRNA detection method, the real-time polymerase chain reaction (RT-PCR) technology. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. The iceberg of genomics: New perspectives in the use of genomics and epigenetics in oncology nursing clinical reasoning. A discursive paper.
- Author
-
Milani, Alessandra, Misurelli, Eliana, Bottaccioli, Anna Giulia, Bottaccioli, Francesco, Lacapra, Silvana, Ciccarelli, Chiara, Magon, Giorgio, and Mazzocco, Ketti
- Subjects
- *
ONCOLOGY nursing , *NURSING theory , *GENETIC testing , *MOLECULAR biology , *NURSING practice , *CANCER patients , *RISK assessment , *GENOMICS , *CLINICAL competence , *CANCER genes , *EPIGENOMICS , *MEDICAL logic - Abstract
Background: Although, there is a wealth of information in the medical literature on the usefulness of genomic testing in assessing risk and its application in medical oncology decision making, there are no theoretical reflections in the nursing field. Aim: To understand the implications of molecular biology in nursing practice and highlight the role of Nursing Theory in guiding nurses' reasoning. Materials and Methods: Searching literature published between 2000 and 2022 in Medline and Google Scholar. Scientific evidence was analysed by the authors expert in different fields. Results: Based on the findings of the literature, concerns have been raised about the proper care of cancer patients who have a genomic risk profile determination. In particular, the absence of theoretical thinking and conceptual models that consider developments in molecular biology and their impact on nursing, in addition to the prevalence of heuristic thinking and the application of clinical patterns in nursing practice, could induce patient misjudgement with inadequate planning of preventive, curative, rehabilitative and educational nursing interventions. Nurses working in the field of oncology should be aware that the risk profile determined by genomics tests is merely the visible and stated portion of the cancer patient: the tip of iceberg. Discussion: This study demonstrates how genomic testing takes into account a fraction of genes discovered in tumour tissue to establish a risk profile. This subset differs, for example, from the social genome, which can determine the risk of dementia, cancer and cardiovascular disease, but in response to social adversity. Nursing theory, which views the environment as a metaparadigm, must consider a conceptual model that can integrate the findings of genomic testing with recommendations from studies on the social genome of humans to make it easier to build nursing treatments that can better reduce these risks. Conclusion: A nursing theoretical discourse on genomics is a paramount requirement for developing effective nursing care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. The palliative clinical specialist radiation therapist: A CAMRT White Paper.
- Author
-
Lavergne, Carrie, Rozanec, Natalie, and Harnett, Nicole
- Subjects
MEDICAL quality control ,HEALTH services accessibility ,CANCER patients ,RADIOTHERAPY ,INTERDISCIPLINARY education ,PALLIATIVE treatment ,ALLIED health personnel - Abstract
Copyright of Journal of Medical Imaging & Radiation Sciences is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
5. Tackling Insomnia Symptoms through Vestibular Stimulation in Patients with Breast Cancer: A Perspective Paper.
- Author
-
Perrier, Joy, Galin, Melvin, Denise, Pierre, Giffard, Bénédicte, and Quarck, Gaëlle
- Subjects
- *
BREAST cancer prognosis , *CANCER chemotherapy , *CIRCADIAN rhythms , *VESTIBULAR apparatus diseases , *CANCER patients , *MELATONIN , *PHYSICAL activity , *HEALTH behavior , *QUALITY of life , *ELECTRIC stimulation , *INSOMNIA , *VESTIBULAR stimulation , *BEHAVIOR modification , *COGNITIVE therapy - Abstract
Simple Summary: Patients with breast cancer frequently complaint from insomnia difficulties that can affect quality of life and cancer progression. Such difficulties may result from rest-activity (i.e., 24 h alternation of sleep and wake) rhythm alterations consistently reported in this pathology. Currently proposed approaches to counter insomnia difficulties in patients with breast cancer have positive effects only on sleep complaints and well-being. Moreover, such approaches may be difficult to implement shortly after chemotherapy. Innovatively, vestibular stimulation would be particularly suited to tackling insomnia symptoms in patients with breast cancer. Indeed, recent reports have shown that vestibular stimulation could improve rest-activity rhythm and sleep in healthy volunteers. This perspective paper aims to support the evidence of using vestibular stimulation to improve rest-activity rhythms and reduce insomnia symptoms in patients with BC, with beneficial effects on quality of life and, potentially, survival. Insomnia symptoms are common among patients with breast cancer (BC; 20–70%) and are predictors of cancer progression and quality of life. Studies have highlighted sleep structure modifications, including increased awakenings and reduced sleep efficiency and total sleep time. Such modifications may result from circadian rhythm alterations consistently reported in this pathology and known as carcinogenic factors, including lower melatonin levels, a flattened diurnal cortisol pattern, and lower rest-activity rhythm amplitude and robustness. Cognitive behavioral therapy and physical activity are the most commonly used non-pharmacological interventions to counter insomnia difficulties in patients with BC. However, their effects on sleep structure remain unclear. Moreover, such approaches may be difficult to implement shortly after chemotherapy. Innovatively, vestibular stimulation would be particularly suited to tackling insomnia symptoms. Indeed, recent reports have shown that vestibular stimulation could resynchronize circadian rhythms and improve deep sleep in healthy volunteers. Moreover, vestibular dysfunction has been reported following chemotherapy. This perspective paper aims to support the evidence of using galvanic vestibular stimulation to resynchronize circadian rhythms and reduce insomnia symptoms in patients with BC, with beneficial effects on quality of life and, potentially, survival. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Digital Life Stories of People With Cancer: Impacts on Research.
- Author
-
Rossi, Silvia, Claudot, Frédérique, Lambert, Aurélien, and Kivits, Joelle
- Subjects
CANCER patients ,PATIENTS' attitudes ,CANCER research ,ELECTRONIC paper ,DIGITAL technology - Abstract
This article examines the influence that digital life stories (DLS) can have on cancer research, using the PARCA1 project as an example. After describing the theoretical framework of DLS, we present the PARCA1 project. The PARCA1 project was anchored in the French context (Grand Est region) and aimed at producing knowledge on patients' experience of the cancer pathway through DLS. It involved 10 patients chosen to favor heterogeneity in profiles and experiences of illness. The paper describes the digital tool and the life stories methodology used to accompany the DLS. Next, it presents the methods and strategies used by participants to complete their DLS and the relationship between people with cancer and the accompanying researcher. Following this, we present (1) the impact of DLS on people with cancer, i.e., their progressive engagement in research, and (2) the impact on research, i.e., the methodological impact of people with cancer on research. In the discussion and conclusion, we explore how DLS can impact individuals who engage in them and their role in research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Getting ready for real‐world use of electronic patient‐reported outcomes (ePROs) for patients with cancer: A National Comprehensive Cancer Network ePRO Workgroup paper.
- Author
-
Cracchiolo, Jennifer R., Arafat, Waddah, Atreja, Ashish, Bruckner, Lauren, Emamekhoo, Hamid, Heinrichs, Tricia, Raldow, Ann C., Smerage, Jeffrey, Stetson, Peter, Sugalski, Jessica, and Tevaarwerk, Amye J.
- Subjects
- *
PATIENT reported outcome measures , *CANCER patients , *PATIENT portals , *ELECTRONIC health records , *PHYSICIANS - Abstract
Electronic patient‐reported outcome (ePRO) programs may offer advantages for patients with cancer, clinicians, health care systems, payors, and society in general; but developing and maintaining an ePRO program will require cancer centers to navigate defining meaningful problems, collecting ePROs, implementing action when those ePROs require intervention without over‐burdening clinicians, and monitoring the successes and failures of their ePRO programs. Physician informaticists from the National Comprehensive Cancer Network Electronic Health Record Advisory Group offer 10 guiding principles to consider when contemplating, building, or refining an ePRO program for patients with cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper.
- Author
-
Samineni, Divya, Venkatakrishnan, Karthik, Othman, Ahmed A., Pithavala, Yazdi K., Poondru, Srinivasu, Patel, Chirag, Vaddady, Pavan, Ankrom, Wendy, Ramanujan, Saroja, Budha, Nageshwar, Wu, Michael, Haddish‐Berhane, Nahor, Fritsch, Holger, Hussain, Azher, Kanodia, Jitendra, Li, Meng, Li, Mengyao, Melhem, Murad, Parikh, Apurvasena, and Upreti, Vijay V.
- Subjects
ANTINEOPLASTIC agents ,DRUG development ,CONSORTIA ,QUALITY of life ,CANCER patients - Abstract
The landscape of oncology drug development has witnessed remarkable advancements over the last few decades, significantly improving clinical outcomes and quality of life for patients with cancer. Project Optimus, introduced by the U.S. Food and Drug Administration, stands as a groundbreaking endeavor to reform dose selection of oncology drugs, presenting both opportunities and challenges for the field. To address complex dose optimization challenges, an Oncology Dose Optimization IQ Working Group was created to characterize current practices, provide recommendations for improvement, develop a clinical toolkit, and engage Health Authorities. Historically, dose selection for cytotoxic chemotherapeutics has focused on the maximum tolerated dose, a paradigm that is less relevant for targeted therapies and new treatment modalities. A survey conducted by this group gathered insights from member companies regarding industry practices in oncology dose optimization. Given oncology drug development is a complex effort with multidimensional optimization and high failure rates due to lack of clinically relevant efficacy, this Working Group advocates for a case‐by‐case approach to inform the timing, specific quantitative targets, and strategies for dose optimization, depending on factors such as disease characteristics, patient population, mechanism of action, including associated resistance mechanisms, and therapeutic index. This white paper highlights the evolving nature of oncology dose optimization, the impact of Project Optimus, and the need for a tailored and evidence‐based approach to optimize oncology drug dosing regimens effectively. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Is routine axillary lymph node dissection needed to tailor systemic treatments for breast cancer patients in the era of molecular oncology? A position paper of the Italian National Association of Breast Surgeons (ANISC).
- Author
-
Rocco, Nicola, Ghilli, Matteo, Curcio, Annalisa, Bortul, Marina, Burlizzi, Stefano, Cabula, Carlo, Cabula, Roberta, Ferrari, Alberta, Folli, Secondo, Fortunato, Lucio, Frittelli, Patrizia, Gentilini, Oreste, Grendele, Sara, Grassi, Massimo Maria, Grossi, Simona, Magnoni, Francesca, Murgo, Roberto, Palli, Dante, Rovera, Francesca, and Sanguinetti, Alessandro
- Subjects
AXILLARY lymph node dissection ,MOLECULAR oncology ,EPIDERMAL growth factor receptors ,SENTINEL lymph node biopsy ,CANCER patients ,BREAST cancer - Abstract
De-escalation of axillary surgery in breast cancer (BC) management began when sentinel lymph node biopsy (SLNB) replaced axillary lymph node dissection (ALND) as standard of care in patients with node-negative BC. The second step consolidated ALND omission in selected subgroups of BC patients with up to two macrometastases and recognized BC molecular and genomic implication in predicting prognosis and planning adjuvant treatment. Outcomes from the recent RxPONDER and monarchE trials have come to challenge the previous cut-off of two SLN in order to inform decisions on systemic therapies for hormone receptor-positive (HR+), human epidermal growth factor receptor type-2 (HER2) negative BC, as the criteria included a cut-off of respectively three and four SLNs. In view of the controversy that this may lift in surgical practice, the Italian National Association of Breast Surgeons (Associazione Nazionale Italiana Senologi Chirurghi, ANISC) reviewed data regarding the latest trials on this topic and proposes an implementation in clinical practice. We reviewed the available literature offering data on the pathological nodal status of cN0 breast cancer patients. The rates of pN2 status in cN0 patients ranges from 3.5 % to 16 %; pre-surgical diagnostic definition of axillary lymph node status in cN0 patients by ultrasound could be useful to inform about a possible involvement of ≥4 lymph nodes in this specific sub-groups of women. The Italian National Association of Breast Surgeons (ANISC) considers that for HR + HER2-/cN0-pN1(sn) BC patients undergoing breast conserving treatment the preoperative workup should be optimized for a more detailed assessment of the axilla and the technique of SLNB should be optimized, if considered appropriate by the surgeon, not considering routine ALND always indicated to determine treatment recommendations according to criteria of eligibility to RxPONDER and monarch-E trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Blood Clot Dynamics and Fibrinolysis Impairment in Cancer: The Role of Plasma Histones and DNA.
- Author
-
Ullah, Matti, Mirshahi, Shahsoltan, Valinattaj Omran, Azadeh, Aldybiat, Iman, Crepaux, Sullyvan, Soria, Jeannette, Contant, Geneviève, Pocard, Marc, and Mirshahi, Massoud
- Subjects
- *
PAPER chromatography , *IN vitro studies , *BLOOD viscosity , *T-test (Statistics) , *DATA analysis , *BLOOD proteins , *BLOOD collection , *RHEOLOGY , *ENZYME-linked immunosorbent assay , *DNA , *CANCER patients , *FIBRIN fibrinogen degradation products , *TISSUE plasminogen activator , *IN vivo studies , *HISTONES , *CHRONIC diseases , *PERMEABILITY , *FIBRINOLYSIS , *CASE-control method , *FIBRINOGEN , *MEMBRANE glycoproteins , *SCANNING electron microscopy , *STATISTICS , *COMPARATIVE studies , *MICROSCOPY , *DATA analysis software , *TUMORS , *THROMBOSIS , *BIOMARKERS , *CELL receptors , *BLOOD - Abstract
Simple Summary: Blood clots are formed when blood vessels are injured. They help stop bleeding and heal wounds, but can also cause serious problems if they block blood flow or break off and travel to other organs. This study investigates how blood clots differ in people with cancer compared to healthy or non-cancerous individuals. This study found that cancer patients have higher levels of histones in their blood, which make their clots stiffer and resistant to lysis. Further, clots formed in cancer patients have higher viscoelastic properties, and hence are harder to break down. These findings suggest that cancer patients have abnormal clotting properties that may increase their risk of developing thrombosis, and evaluating these properties can be helpful in detecting cancer. Background: Blood viscoelasticity and plasma protein levels can play an important role in the diagnosis and prognosis of cancer. However, the role of histones and DNA in modulating blood clot properties remains to be investigated. This study investigates the differences in blood viscoelasticity and plasma protein levels among cancer patients, individuals with other diseases, and healthy individuals. Methods: Blood samples were collected from 101 participants, including 45 cancer patients, 22 healthy individuals, and 34 individuals with other diseases. Rheological properties of clots formed in vitro by reconstituted elements of fibrinogen or plasma were analyzed with an Anton Paar Rheometer, USA. Plasma protein levels of D-dimer, TPA, EPCR, fibrinogen, and histone H3 were measured through ELISA. Blood clots were formed with or without DNA and histones (H3) by adding thrombin and calcium to plasma samples, and were evaluated for viscoelasticity, permeability, and degradation. Results: Cancer patients show higher blood viscoelasticity and plasma D-dimer levels compared to healthy individuals and individuals with other diseases. Our in vitro analysis showed that the addition of histone to the plasma results in a significant decrease in viscoelasticity and mean fiber thickness of the clot formed thereafter. In parallel studies, using plasma from patients, DNA and histones were detected in fibrin clots and were associated with less degradation by t-PA. Moreover, our results show that the presence of DNA and histones not only increases clots' permeability, but also makes them more prone to degradation. Conclusions: Plasma histones and DNA affect the structure of the clot formed and induce defective fibrinolysis. Moreover, the increased viscoelastic properties of plasma from cancer patients can be used as potential biomarkers in cancer prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Intravenous iron and iron deficiency anemia in patients with gastrointestinal cancer: A systematic review.
- Author
-
Nandakumar, Shankavi, Singh, Navreet, Tharani, Alliya Remtulla, Pankiw, Maya, and Brezden-Masley, Christine
- Subjects
IRON deficiency anemia ,GASTROINTESTINAL cancer ,CANCER patients ,ERYTHROCYTES ,IRON supplements ,SURGICAL complications ,CONFERENCE papers - Abstract
Background: Iron deficiency anemia (IDA) is a prevalent hematological complication associated with gastrointestinal (GI) cancers due to an increased loss of iron and decreased iron absorption. The purpose of this systematic review is to evaluate the use of parenteral iron to treat IDA in patients with GI cancer. Methods: PubMed, Cochrane, EMBASE, CINHAL and Scopus were searched from January 1, 2010 to September 29, 2023 with no language restrictions. We excluded editorials, case reports, abstracts, conference papers, and poster presentations. Studies were included if they discussed IDA, GI neoplasms, use of iron supplementation (with or without erythropoietin-stimulating agents [ESAs]), defined anemia and had an adult patient population. We assessed the efficacy of parenteral iron in comparison to other iron supplementation methods when treating IDA in patients with GI cancer. The Cochrane Risk of Bias Tool 2 (RoB 2) and the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) assessment tools were used to assess the quality of the included studies. Moreover, the Cochrane Effective Practice and Organization data collection form was used to collect pertinent study information. Results: Our search yielded 3,969 studies across all databases. Twenty-one studies were included (6 randomized control trials; 15 non-randomized studies). Of the 15 studies evaluating hemoglobin (Hb) response, seven studies found an increase in Hb levels when patients were treated with IV iron. The 14 studies evaluating red blood cell (RBC) transfusion rates found conflicting differences in RBC transfusion needs when treated with IV iron. Studies analyzing health related outcomes typically found an increase in quality of life and decreased post-operative complications. Discussion: This review demonstrates improved outcomes of IDA in patients with GI cancer treated with IV iron instead of other iron supplementation methods. Timely diagnosis and appropriate IDA management can greatly improve quality of life in this patient population, especially if myelosuppressive chemotherapy is required. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. The use of biomarkers to stratify surgical care in women with ovarian cancer: Scientific Impact Paper No. 69 May 2022.
- Author
-
Phelps, D. L., Borley, J. V., Brown, R., Takáts, Z., and Ghaem‐Maghami, S.
- Subjects
- *
OVARIAN cancer , *CANCER patients , *CA 125 test , *BIOMARKERS , *BIOMOLECULES , *CANCER prognosis , *CANCER treatment - Abstract
Plain language summary: Biomarkers may offer unforeseen insights into clinical diagnosis, as well as the likely course and outcome of a condition. In this paper, the focus is on the use of biological molecules found in body fluids or tissues for diagnosis and prediction of outcome in ovarian cancer patients. In cancer care, biomarkers are being used to develop personalised treatment plans for patients based on the unique characteristics of their tumour. This tailoring of care can be used to pursue specific targets identified by biomarkers, or treat the patient according to specific tumour characteristics. Surgery is one of the core treatments for ovarian cancer, whether it is offered in primary surgery or following chemotherapy in delayed surgery. Biomarkers already exist to guide the treatment of tumours with chemotherapy, but very little research has determined the value of biomarkers in tailoring surgical care for ovarian cancer. Such research is required to identify new biomarkers and assess their effectiveness in a clinical setting as well as to help identify specific tumour types to guide surgery. Biomarkers could help to determine the success of removing the disease surgically, or help to identify tumour deposits that persist after chemotherapy. All of these aspects would improve current practice. This Scientific Impact Paper highlights research that may pave the way towards bespoke surgery according to the biological characteristics of a tumour and aid gynaecological oncologists to provide surgical treatment according to individual need, rather than a blanket approach for all. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Developing an educational resource for gynecological cancer survivors and their caregivers: A methods and experience paper.
- Author
-
Galica, Jacqueline, Silva, Amina, and Robb, Kathleen
- Subjects
PROFESSIONAL practice ,CAREGIVERS ,PHYSICIAN-patient relations ,RESEARCH methodology ,EVIDENCE-based medicine ,CANCER patients ,HUMAN services programs ,CONCEPTUAL structures ,MEDICAL protocols ,INTERPROFESSIONAL relations ,PATIENT-professional relations ,FEMALE reproductive organ tumors - Abstract
Copyright of Canadian Oncology Nursing Journal is the property of Pappin Communications and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
14. Best Paper 40–50.
- Subjects
- *
TOTAL body irradiation , *VOLUMETRIC-modulated arc therapy , *PROSTATE cancer , *CANCER patients , *NON-small-cell lung carcinoma - Abstract
There was a significant difference in the delay of radiation treatment delivery by 3 weeks (15 fractions) in COVID-19-positive patients compared to only 1 week delay in COVID-19-negative patients. The disease was clinically controlled in 56 patients (42.42%) of the COVID-19-positive patients, and the patients reported locoregional disease progression in 34 patients (25.75%). There was a longer duration of treatment interruptions in the COVID-19-positive patients, mostly in second wave of the pandemic, leading to fewer patients completing the radiation treatment and thereby increased locoregional disease progression. The study was conducted to present the real-world analysis of the effect of treatment interruptions on the outcomes of patients treated with radiation therapy during all the three waves of the COVID-19 pandemic in a tertiary care institute in India. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
15. Biographical Renewal and its Facilitators in Cancer Survivorship: A Conceptual Paper.
- Author
-
Jadhav, Bhoomika N. and Azeez, E. P. Abdul
- Subjects
MEDICAL protocols ,ATTITUDES toward illness ,PALLIATIVE treatment ,CANCER patient medical care ,PRESUMPTIONS (Law) ,CANCER patients ,CAREGIVERS ,QUALITY of life ,HEALTH promotion ,SELF-perception - Abstract
Experiencing cancer impinges life in several ways. Research on the biographical implications of cancer has focused on its disruptive nature. Biographical renewal is not given full attention despite existing literature on positive transformations after cancer. This conceptual paper presents an account of biographical renewal in the milieu of cancer survivorship. Further, we discussed some crucial facilitators that promote the biographical renewal. Caregivers may consider biographical renewal as a substantially new goal in the survivorship care plan to improve patients' quality of life. The discussion is designed to foster an understanding of biographical renewal for the psychosocial practice by professionals with cancer patients, survivors, and their caregivers – formal and informal, to provide comprehensive care during cancer survivorship. Implications for palliative care are also discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Cervical Cancer Stigma Among Caribbean Population: A Descriptive Paper.
- Author
-
Thomas-Purcell, Kamilah, Bailey, Althea, Sealy, Diadrey-Anne, Song, Gaole, and Ashing, Kimlin Tam
- Subjects
CERVICAL cancer ,HUMAN papillomavirus vaccines ,CANCER patients ,SOCIAL norms ,SOCIAL background - Abstract
Objectives: Cervical cancer prevention practices are desperately low in the Caribbean. This study aims to describe the cervical cancer stigma and to evaluate the influence of the prevention practices among the Caribbean non-patient population in Jamaica, Grenada, Trinidad and Tobago. Methods: A cross-sectional study involving 1,207 participants was conducted using a culturally trans-created Cancer Stigma Scale for the Caribbean context and supplemented with questions on cervical cancer and HPV/HPV vaccine knowledge and beliefs. Data collection took place online from October 2022 to March 2023. Results: Participants are young, single, well-educated, and have stable financial resources. Over a quarter (26.4%) agreed women with cervical cancer are more isolated in their country. Almost half (47%) of respondents agreed cultural background plays a big part in how they feel about illness and getting well. One in six participants believe women with cervical cancer are treated with less respect than usual by others in their country. Conclusion: Cancer stigma of cervical cancer exists in Jamaica, Trinidad and Tobago, and Grenada. Particularly, cultural background and social norms are closely linked to stigma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Improving Influenza Vaccination Coverage in Patients with Cancer: A Position Paper from a Multidisciplinary Expert Group.
- Author
-
Bonanni, Paolo, Maio, Michele, Beretta, Giordano D., Icardi, Giancarlo, Rossi, Alessandro, and Cinieri, Saverio
- Subjects
INFLUENZA vaccines ,VACCINATION coverage ,MEDICAL personnel ,VACCINATION ,CANCER patients - Abstract
Patients with cancer can be immunocompromised because of their disease and/or due to anticancer therapy. In this population, severe influenza virus infections are associated with an elevated risk of morbidity and mortality. Influenza vaccination is therefore highly recommended in cancer patients, including those receiving anticancer therapy. However, vaccination coverage remains far below the recommended target for vulnerable subjects. Six specialists in oncology, hematology, immunology, and public health/vaccinology convened with the objective of developing strategies, based on evidence and clinical experience, for improving influenza vaccination coverage in cancer patients. This viewpoint provides an overview of current influenza vaccination recommendations in cancer patients, discusses barriers to vaccination coverage, and presents strategies for overcoming said barriers. New immunization issues raised by the COVID-19 pandemic are also addressed. Future directions include improving public education on influenza vaccination, providing the media with accurate information, improving knowledge among healthcare professionals, improving access to vaccines for cancer patients, co-administration of the influenza and COVID-19 vaccines, increased collaboration between oncologists and other health professionals, increased accessibility of digital vaccination registries to specialists, shared information platforms, and promoting immunization campaigns by healthcare systems with the support of scientific societies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. E-Cigarettes: A Scientometric Assessment of Global Publications Output during 2001-18.
- Author
-
Gupta, B. M., Mueen Ahmed, K. K., and Visakhi, P.
- Subjects
ELECTRONIC cigarettes ,CITATION indexes ,NICOTINE ,CANCER patients ,TOBACCO - Abstract
The paper makes assessment of global e-cigarette publications (3885 publications) trends over the past 18 years (2001-8) via a bibliometric analysis, using Scopus database. The paper further provides an insight into qualitative performance of e-cigarettes research in terms of qualitative indicators, such as relative citation index, citations per paper, highly cited papers, top 15 global organizations and authors in the field, most favored subjects in the field. E-cigarettes annual and nine-year cumulative global publication output registered 113.60% and 7570.0% growth during the last 18 years and its citation impact averaged to 18.71 citations per paper. 89.63% share of the global research output and more than 100% share of global citation output in the field emanates from top 10 (among 37 participating countries) during 2001-18. Seven (out of top 10) countries registered relative citation index above their global average of 1.29: Canada and Italy (2.32 each), Greece (1.75), Australia (1.54), U.K. and Switzerland (1.42 each) and France (1.30) during 2001-18. Medicine is the most preferred subject on e-cigarettes research with 81.75% global publications share, followed distantly by pharmacology, toxicology and pharmaceutics (13.15%), social sciences (9.146%), environment science (7.26%), etc. during this period. Among 525 organizations and 729 authors participating in e-cigarettes research, the top 15 organizations and the authors collectively contributed 26.64% and 13.64% global publication share and 47.78% and 33.25% global citation share, respectively during 2001-18. USA and U.K. were the leading global organizations with global publications share of 52.15% and 12.54%. University of California, San Francisco, USA and University of North Carolina at Chapel Hills, USA were the leading organizations with 135 and 87 papers. Roswell Park Cancer Institute, USA (53.79 and 2.88) and Food and Drug Administration, MD, USA (42.33 and 2.26) were the two leading organizations in terms of citation impact per paper and relative citation index. R. Polosa (61 papers) and K.E. Farsalinos (45 papers) were the two most productive authors on the subject. M.L. Goniewicz (77.02 and 4.12) and S.A. Glantz (69.50 and 3.71) were the two leading authors in terms of citation impact per paper and relative citation index. Nicotine and Tobacco Research (184 papers) and Tobacco Control (168 papers) were the leading journals (among 305 participating journals) publishing on this theme. 141 papers (among 3885 total papers) registered 100 to 2902 citations per paper, cumulating to a total 31459 citations, averaging to 223.11 citations per paper. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. SINPE Position Paper on the use of home parenteral nutrition in cancer patients.
- Author
-
Bozzetti, Federico, Caccialanza, Riccardo, Cotogni, Paolo, Finocchiaro, Concetta, Pironi, Loris, Santarpia, Lidia, and Zanetti, Michela
- Subjects
- *
SHORT bowel syndrome , *PARENTERAL feeding , *CANCER patients , *ENTERAL feeding , *CENTRAL line-associated bloodstream infections , *CENTRAL venous catheters - Published
- 2022
- Full Text
- View/download PDF
20. If health organisations and staff engage in research, does healthcare improve? Strengthening the evidence base through systematic reviews.
- Author
-
Boaz, Annette, Goodenough, Belinda, Hanney, Stephen, and Soper, Bryony
- Subjects
MEDICAL personnel ,HEALTH equity ,CANCER patients ,ENGLISH language ,ORGANIZATIONAL research - Abstract
Background: There is an often-held assumption that the engagement of clinicians and healthcare organizations in research improves healthcare performance at various levels. Previous reviews found up to 28 studies suggesting a positive association between the engagement of individuals and healthcare organizations in research and improvements in healthcare performance. The current study sought to provide an update. Methods: We updated our existing published systematic review by again addressing the question: Does research engagement (by clinicians and organizations) improve healthcare performance? The search covered the period 1 January 2012 to March 2024, in two phases. First, the formal updated search ran from 1 January 2012 to 31 May 2020, in any healthcare setting or country and focussed on English language publications. In this phase two searches identified 66 901 records. Later, a further check of key journals and citations to identified papers ran from May 2020 to March 2024. In total, 168 papers progressed to full-text appraisal; 62 were identified for inclusion in the update. Then we combined papers from our original and updated reviews. Results: In the combined review, the literature is dominated by papers from the United States (50/95) and mostly drawn from the Global North. Papers cover various clinical fields, with more on cancer than any other field; 86 of the 95 papers report positive results, of which 70 are purely positive and 16 positive/mixed, meaning there are some negative elements (i.e. aspects where there is a lack of healthcare improvement) in their findings. Conclusions: The updated review collates a substantial pool of studies, especially when combined with our original review, which are largely positive in terms of the impact of research engagement on processes of care and patient outcomes. Of the potential engagement mechanisms, the review highlights the important role played by research networks. The review also identifies various papers which consider how far there is a "dose effect" from differing amounts of research engagement. Additional lessons come from analyses of equity issues and negative papers. This review provides further evidence of contributions played by systems level research investments such as research networks on processes of care and patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Findings on Cancer Described by Berengere Beauplet and Colleagues [Dealing with the lack of evidence to treat depression in older patients with cancer: French Societies of Geriatric Oncology (SOFOG) and PsychoOncology (SFFPO) position paper ...]
- Subjects
Elderly patients ,Depression (Mood disorder) ,Physical fitness ,Cancer ,Cancer patients ,Health - Abstract
2020 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Cancer. According to news reporting originating from [...]
- Published
- 2020
22. Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper.
- Author
-
Cooksley, Tim, Font, Carme, Scotte, Florian, Escalante, Carmen, Johnson, Leslie, Anderson, Ronald, and Rapoport, Bernardo
- Subjects
- *
FEBRILE neutropenia , *COVID-19 , *COVID-19 pandemic , *CANCER patients , *HEALTH facilities , *SARS-CoV-2 - Abstract
Patients with cancer are at higher risk of more severe COVID-19 infection and have more associated complications. The position paper describes the management of cancer patients, especially those receiving anticancer treatment, during the COVID-19 pandemic. Dyspnea is a common emergency presentation in patients with cancer with a wide range of differential diagnoses, including pulmonary embolism, pleural disease, lymphangitis, and infection, of which SARS-CoV-2 is now a pathogen to be considered. Screening interviews to determine whether patients may be infected with COVID-19 are imperative to prevent the spread of infection, especially within healthcare facilities. Cancer patients testing positive with no or minimal symptoms may be monitored from home. Telemedicine is an option to aid in following patients without potential exposure. Management of complications of systemic anticancer treatment, such as febrile neutropenia (FN), is of particular importance during the COVID-19 pandemic where clinicians aim to minimize patients' risk of infection and need for hospital visits. Outpatient management of patients with low-risk FN is a safe and effective strategy. Although the MASCC score has not been validated in patients with suspected or confirmed SARS-CoV-2, it has nevertheless performed well in patients with a range of infective illnesses and, accordingly, it is reasonable to expect efficacy in the clinical setting of COVID-19. Risk stratification of patients presenting with FN is a vital tenet of the evolving sepsis and pandemic strategy, necessitating access to locally formulated services based on MASCC and other national and international guidelines. Innovative oncology services will need to utilize telemedicine, hospital at home, and ambulatory care services approaches not only to limit the number of hospital visits but also to anticipate the complications of the anticancer treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. GlycoMimetics announces publication of paper supporting GMI-1359 clinical trial
- Subjects
Cancer prevention ,Cells (Biology) ,Clinical trials ,Cancer metastasis ,Cancer patients ,Breast cancer ,Tumors ,Stem cells ,Business ,News, opinion and commentary - Abstract
GlycoMimetics announced the publication of a paper in Nature Cell Biology that describes how tumor cells engage specific stromal components, most notably E-selectin, for propagation and outgrowth. The paper provides [...]
- Published
- 2019
24. Corcept distributes white paper disputing 'speculator' claims
- Subjects
Drug approval ,Health ,Physicians ,Cancer patients ,Business ,News, opinion and commentary ,Korlym (Medication) - Abstract
In a regulatory filing, Corcept Therapeutics reported that it is disseminating a white paper entitled 'Some Important Facts about Corcept, Physicians and Patients.' The white paper states in part: 'Our [...]
- Published
- 2019
25. Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers.
- Author
-
Schubert, Nil A., Lowery, Caitlin D., Bergthold, Guillaume, Koster, Jan, Eleveld, Thomas F., Rodríguez, Ana, Jones, David T.W., Vassal, Gilles, Stancato, Louis F., Pfister, Stefan M., Caron, Hubert N., and Molenaar, Jan J.
- Subjects
- *
ANTINEOPLASTIC agents , *CANCER patients , *MEDLINE , *ONLINE information services , *PEDIATRICS , *TUMORS in children , *SYSTEMATIC reviews - Abstract
Children with cancer are in urgent need of new therapies, as approximately 25% of patients experience a relapse and 20% succumb to their disease. Moreover, the majority of survivors suffer from clinically relevant health problems. Repurposing of targeted agents developed for adult indications could provide novel therapeutic options for paediatric cancer patients. To prioritise targeted drugs for paediatric clinical development, we applied a systematic review methodology to develop a Target Actionability Review (TAR) strategy. These TARs assess the strength and completeness of published preclinical proof-of-concept (PoC) data by structured critical appraisal of and summarising the available scientific literature for a specific target (pathway) and the associated drugs in paediatric tumours. A sensitive literature search in PubMed was performed and relevant papers were identified. For each paper, the individual experimental findings were extracted, marked for paediatric tumour type and categorised into nine separate PoC data modules. Each experimental finding was scored for experimental outcome and quality independently by two reviewers; discrepancies were assessed by a third reviewer and resolved by adjudication. Scores corresponding to one PoC module were merged for each tumour type and visualised in a heat map matrix in the publicly available R2 data portal [r2.amc.nl]. To test our TAR methodology, we conducted a pilot study on MDM2 and TP53. The heat map generated from analysis of 161 publications provides a rationale to support drug development in specific paediatric solid and brain tumour types. Furthermore, our review highlights tumour types where preclinical data are incomplete or lacking and for which additional preclinical testing is advisable. • A new strategy to review literature on targeted compounds in paediatric cancer. • Results help to guide and prioritise clinical development of novel targeted agents. • Outcomes are visualised in a publicly available, interactive heat map. • We applied this unique methodology to MDM2 and TP53 and MDM2 inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.
- Author
-
Stacchiotti, Silvia, Frezza, Anna Maria, Blay, Jean‐Yves, Baldini, Elizabeth H., Bonvalot, Sylvie, Bovée, Judith V. M. G., Callegaro, Dario, Casali, Paolo G., Chiang, RuRu Chun‐ju, Demetri, George D., Demicco, Elisabeth G., Desai, Jayesh, Eriksson, Mikael, Gelderblom, Hans, George, Suzanne, Gounder, Mrinal M., Gronchi, Alessandro, Gupta, Abha, Haas, Rick L., and Hayes‐Jardon, Andrea
- Subjects
- *
OSTEOSARCOMA , *SARCOMA , *CONNECTIVE tissues , *RARE diseases , *DRUG development , *CANCER patients - Abstract
Background: Among sarcomas, which are rare cancers, many types are exceedingly rare; however, a definition of ultra‐rare cancers has not been established. The problem of ultra‐rare sarcomas is particularly relevant because they represent unique diseases, and their rarity poses major challenges for diagnosis, understanding disease biology, generating clinical evidence to support new drug development, and achieving formal authorization for novel therapies. Methods: The Connective Tissue Oncology Society promoted a consensus effort in November 2019 to establish how to define ultra‐rare sarcomas through expert consensus and epidemiologic data and to work out a comprehensive list of these diseases. The list of ultra‐rare sarcomas was based on the 2020 World Health Organization classification, The incidence rates were estimated using the Information Network on Rare Cancers (RARECARENet) database and NETSARC (the French Sarcoma Network's clinical‐pathologic registry). Incidence rates were further validated in collaboration with the Asian cancer registries of Japan, Korea, and Taiwan. Results: It was agreed that the best criterion for a definition of ultra‐rare sarcomas would be incidence. Ultra‐rare sarcomas were defined as those with an incidence of approximately ≤1 per 1,000,000, to include those entities whose rarity renders them extremely difficult to conduct well powered, prospective clinical studies. On the basis of this threshold, a list of ultra‐rare sarcomas was defined, which comprised 56 soft tissue sarcoma types and 21 bone sarcoma types. conclusions: Altogether, the incidence of ultra‐rare sarcomas accounts for roughly 20% of all soft tissue and bone sarcomas. This confirms that the challenges inherent in ultra‐rare sarcomas affect large numbers of patients. The list of ultra‐rare sarcomas, defined as those sarcomas with an incidence ≤1 per 1,000,000, comprises 56 soft tissue sarcoma and 21 bone sarcoma types. The incidence of ultra‐rare sarcomas accounts for roughly 20% of all soft tissue and bone sarcomas, confirming that challenges inherent to ultra‐rare sarcomas affect large numbers of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. A usability study to test the effectiveness, efficiency and simplicity of a newly developed Internet-based Exercise-focused Health App for Lung cancer survivors (iEXHALE): Protocol paper.
- Author
-
Henshall, Catherine, Davey, Zoe, Jacelon, Cynthia, and Martin, Clare
- Subjects
- *
TREATMENT of lung tumors , *CANCER patients , *EXERCISE therapy , *INTERNET , *HEALTH self-care , *ASSISTIVE technology , *SURVEYS , *EVIDENCE-based medicine , *PROFESSIONAL practice , *USER-centered system design , *MOBILE apps - Abstract
The Internet-based Exercise-focused Health App for Lung cancer survivors (iEXHALE) is a mobile web app being developed to provide lung cancer survivors with an algorithm-based, tailor-made, self-management programme to inform their exercise choices and improve symptom severity. The aim of this protocol paper is to detail the plan for conducting the usability study to test the effectiveness, efficiency and simplicity of an exercise-focused self-management mobile web app for lung cancer survivors. The mixed methods study will consist of three consecutive phases, each interspersed with elements of data analysis and app prototype redevelopment. The study will take place in Oxford, United Kingdom. Ethical approvals have been obtained. The study will contribute to lung cancer survivorship research and is important in the app developmental process. This study contributes to the international forum for the exchange of practice, innovation and research, increases transparency in mobile health developmental processes and contributes to the methodological evidence base. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. New Otolaryngology Findings Reported from University Hospital Donostia (Systemic review of international guidelines for perioperative antibiotic prophylaxis in Head & Neck Surgery. A YO-IFOS Head & Neck Study Group Position Paper)
- Subjects
Surgery ,Prophylaxis ,Physical fitness ,Antibiotics ,Obesity ,Infection ,Editors ,Cancer patients ,Health - Abstract
2019 JUL 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Health and Medicine - Otolaryngology. According to [...]
- Published
- 2019
29. Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
- Author
-
Cazzaniga, Marina Elena, Ciaccio, Antonio, Danesi, Romano, Duhoux, Francois P., Girmenia, Corrado, Zaman, Kalhil, Lindman, Henrik, Luppi, Fabrizio, Mavroudis, Dimitrios, Paris, Ida, Olubukola, Ayodele, Samreen, Ahmed, Schem, Christian, Singer, Christian, and Snegovoy, Anton
- Subjects
HORMONE receptor positive breast cancer ,CYCLIN-dependent kinases ,METASTATIC breast cancer ,HORMONE receptors ,CYCLIN-dependent kinase inhibitors ,CANCER patients - Abstract
The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclindependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy. Currently, no guidelines are available to monitor and manage potential long-term toxicities associated with the use of these drugs. A multidisciplinary panel of European oncologists, was supported by a pharmacologist, a hematologist, a hepatologist and a pulmonologist to discuss the management of long-term toxicities, based on the literature review and their clinical experience. The panel provided detailed roadmaps to manage long-term toxicities associated with the use of CDK4/6 inhibitors in clinical practice. Knowing the frequency and characteristics of the toxicity profile associated with each CDK4/6 inhibitor is important in the decision-making process to match the right drug to the right patient. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Dealing with the lack of evidence to treat depression in older patients with cancer: French Societies of Geriatric Oncology (SOFOG) and PsychoOncology (SFFPO) position paper based on a systematic review.
- Author
-
Beauplet, Bérengère, Soulie, Ophélie, Niemier, Jean-Yves, Pons-Peyneau, Cécile, Belhadi, Drifa, Couffignal, Camille, and Fossey-Diaz, Virginie
- Subjects
- *
OLDER patients , *GERIATRIC oncology , *MEDICAL personnel , *CANCER patients , *MENTAL depression - Abstract
Introduction: Depression symptoms, frequently diagnosed in older patients with cancer, impacts on oncological treatment feasibility. The Francophone Society of Geriatric Oncology (SOFOG) has initiated a systematic review on depression treatment in older patients with cancer, to advocate guidelines. Data sources: Medline via PubMed, Embase, CENTRAL. Methods: We included randomized and non-randomized controlled trials, reviews and meta-analysis, retrospective and prospective cohort studies, qualitative studies, and guidelines published between January 2013 and December 2018 that involved depression with cancer in which the entire sample or a sub-group aged 65 and above. Efficacy and tolerance of depression treatment were examined, as a primary or secondary outcome, among articles published in French or English. Results: Of 3171 references, only seven studies met our eligibility criteria. This systematic review reveals a lack of evidence-based knowledge in this field, preventing from making any recommendations on drug and non-drug therapies. It has highlighted the need for multidisciplinary collaboration with the French and Francophone Society of Psycho-Oncology. Conclusion: In clinical practice, we advise health professionals to use the screening process not as a result but rather as an opportunity to engage with the patient and also to question the need for antidepressants and non-drug therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Knowledge, attitudes and intention on fertility preservation among breast cancer patients.
- Author
-
Ko, Jennifer K. Y., Cheung, Charleen S. Y., Cheng, Heidi H. Y., Yung, Sofie S. F., Ng, Ting Ying, Tin, Winnie W. Y., Yuen, Ho Yan, Lam, Martin H. C., Chan, Ann S. Y., Fung, Sara W. W., Man, Vivian C. M., Kwong, Ava, and Ng, Ernest H. Y.
- Subjects
FERTILITY preservation ,FAMILY planning ,BREAST cancer ,CANCER patients ,ELECTRONIC paper ,SUPPORT groups ,HUMAN fertility - Abstract
Breast cancer is the most common cancer in reproductive age women. The aim of this study is to assess the knowledge, attitude and intention on fertility preservation among women diagnosed to have breast cancer. This is a multi-centre cross-sectional questionnaire study. Reproductive age women diagnosed with breast cancer attending Oncology, Breast Surgery and Gynaecology Clinics and support groups were invited to participate. Women filled in paper or electronic form of the questionnaire. 461 women were recruited and 421 women returned the questionnaire. Overall, 181/410 (44.1%) women had heard of fertility preservation. Younger age and higher education level were significantly associated with increased awareness of fertility preservation. Awareness and acceptance of the different fertility preservation methods in reproductive age women with breast cancer was suboptimal. However, 46.1% women felt that their fertility concerns affected their decision for cancer treatment in some way. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Italian expert consensus paper on the management of patients with actinic keratoses.
- Author
-
Moscarella, Elvira, Di Brizzi, Eugenia Veronica, Casari, Alice, De Giorgi, Vincenzo, Di Meo, Nicola, Fargnoli, Maria Concetta, Lacarrubba, Francesco, Micali, Giuseppe, Pellacani, Giovanni, Peris, Ketty, Piaserico, Stefano, Calzavara‐Pinton, Piergiacomo, Quaglino, Pietro, Sollena, Pietro, Zalaudek, Iris, Zane, Cristina, and Argenziano, Giuseppe
- Subjects
- *
ACTINIC keratosis , *KERATOSIS , *CANCER patients , *PHOTODYNAMIC therapy , *SQUAMOUS cell carcinoma , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Two round tables involving experts were organized in order to reach a consensus on the management of patients with actinic keratosis (AK). In the first, seven clinical questions were selected and analyzed by a systematic literature review, using a Population, Intervention, Control, and Outcomes framework; in the second, the experts discussed relevant evidences and a consensus statement for each question was developed. Consensus was reached among experts on how to best treat AK patients with respect to different clinical scenarios and special populations. Lesion‐directed treatments are preferred in patients with few AKs. Patients with multiple AKs are challenging, with more than one treatment usually needed to achieve complete lesion clearance or a high lesion response rate, therapy should be personalized, based on previous treatments, patient, and lesion characteristics. Methyl aminolevulinate‐PDT, DL (day light) PDT, and imiquimod cream were demonstrated to have the lowest percentage of new AKs after post treatment follow‐up. For IMQ 5% and 3.75%, a higher intensity of skin reactions is associated with higher efficacy. Photodynamic therapy (PDT) is the most studied treatment for AKs on the arms. Regular sunscreen use helps preventing new AKs. Oral nicotinamide 500 mg twice daily, systemic retinoids and regular sunscreen use were demonstrated to reduce the number of new squamous cell carcinomas in patients with AKs. Limited evidence is available for the treatment of AKs in organ transplant recipients. There is no evidence in favor or against the use of any of the available treatments in patients suffering from hematological cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Proceed with Caution: Transition from Paper to Computerized Pain Body Maps.
- Author
-
Jaatun, Ellen A.A., Haugen, Dagny F., Dahl, Yngve, and Kofod-Petersen, Anders
- Subjects
AUTOMATION ,PAIN ,CANCER patients ,IPADS ,SYSTEMS design ,COMPARATIVE studies - Abstract
Abstract: Patients with advanced-stage cancer often have a high symptom burden and reduced functional status, implying that the patients themselves should be involved in development and testing of interactive assessment tools. This paper reports on an assessment of use of a pain tool, which led to changes in both medium and program in order to adapt to the patients’ needs and abilities. Our study shows how a change in medium for pain assessment from paper via laptop to iPad affects the interaction with the tool on important aspects of use. We also show how changes of medium affect the readability of the output for health care workers. We achieved better results with an iPad-based pain assessment tool developed through user-centered design compared to both a paper-based and conventional laptop-based tool. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
34. Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper.
- Author
-
Silvestris, Nicola, Argentiero, Antonella, Cosmai, Laura, Porta, Camillo, Gesualdo, Loreto, Brunori, Giuliano, Brunetti, Oronzo, Rampino, Teresa, Secondino, Simona, Rizzo, Gianpiero, and Pedrazzoli, Paolo
- Subjects
- *
CHRONICALLY ill , *CANCER patients , *KIDNEY diseases , *CHRONIC kidney failure , *CANCER treatment , *BIOAVAILABILITY - Abstract
• Most of target agents can be used with the same patterns and the same dosage in mild and moderate renal impairment. • It is difficult to draw scientific supported conclusions in cancer patients with severe, end-stage renal disease or HD. • Although renal toxicity of biological agents can be overcome by HD treatment, caution in these settings is still warranted. • A strong cooperation among oncologists, nephrologists and pharmacists is unavoidable to provide an optimal management for these patients. The increasing availability of novel biological anticancer agents has greatly improved the outcome of several cancer patients; unfortunately, data regarding efficacy, safety and pharmacokinetics of many of these agents in patients with chronic renal disease or on hemodialysis are scanty. Furthermore these results are controversial and a treatment strategy has not yet been established. Therefore, the Associazione Italiana di Oncologia Medica and the Società italiana di Nefrologia undertook the present work aiming at providing health professionals with a tool for easier clinical management of target therapies in this setting of patients. A web-based search of MEDLINE/PubMed library data published from 2000 to June 2018 has been performed. More than one hundred papers, including recommendations and expert opinions, were selected and discussed by the authors. A panel of experts provided additional biological and clinical information, helping in clarifying some issues in the absence of clear-cut information from the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. New Data from S.J. Grant et al Illuminate Findings in Cancer Care (Guidance for establishing an integrative oncology service in the Australian healthcare setting-a discussion paper)
- Subjects
Physical fitness ,Alternative medicine ,Cancer patients ,Health - Abstract
2018 JAN 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Oncology - Cancer Care have been presented. According to [...]
- Published
- 2018
36. Enhancing collaboration between geriatricians, oncologists, and pharmacists to optimize medication therapy in older adults with cancer: A position paper from SOFOG-SFPO.
- Author
-
Herledan, Chloé, Toulemonde, Anne, Clairet, Anne-Laure, Boulin, Mathieu, Falandry, Claire, Decker, Laure De, Rioufol, Catherine, Bayle, Arnaud, and Bertrand, Nicolas
- Subjects
- *
OLDER people , *CANCER patients , *PHARMACISTS , *GERIATRICIANS , *ONCOLOGISTS , *REMINISCENCE therapy - Abstract
Optimizing anticancer treatment and medication therapy in older patients with cancer requires a multidisciplinary approach, with a strong collaboration between geriatricians, oncologists and pharmacists. While all patients can benefit, some clinical situations seem to be high-priority. Careful attention should be given to patients with cardiovascular comorbidities and/or diabetes, which are prone to decompensate during anticancer treatment and often involve multiple medications. Another great concern is the risk of falls, closely related to polypharmacy, hence the need for a comprehensive medication review. Managing the pharmacological treatment of depression is also challenging and require shared expertise. Finally, pharmacists can prove valuable in situations of adherence difficulties or use of complementary medicines. Collaborative practice should begin at initiation of anticancer treatment and continue throughout the care pathway, as continuous reassessment is essential. Although the integration of pharmacists in multidisciplinary teams is often challenged by funding, collaborative should still be strongly encouraged. [Display omitted] • Reducing medication iatrogenesis is a major challenge to optimize cancer treatment. • Geriatrician/oncologist and pharmacist collaboration is crucial in geriatric oncology. • Collaborative practice should be incorporated throughout the whole care pathway. • Economic evaluations and pricing models is needed to support this collaboration. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
- Subjects
Thyroid diseases -- Prognosis ,MicroRNA ,Medical research ,Cancer patients ,General interest ,News, opinion and commentary - Abstract
Parsippany: Interpace Biosciences, Inc. has issued the following press release: Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company's ThyGeNEXT(r) [...]
- Published
- 2020
38. Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
- Subjects
Thyroid diseases ,Medical research ,MicroRNA ,Associations ,Cancer ,Cancer patients ,Business, international ,Law - Abstract
(GlobeNewswire) - Interpace Biosciences, Inc. (Nasdaq:IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the companys ThyGeNEXT and ThyraMIR tests in the Journal of the American [...]
- Published
- 2020
39. Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
- Subjects
Thyroid diseases ,Medical research ,MicroRNA ,Associations ,Cancer ,Cancer patients ,Banking, finance and accounting industries ,Business - Abstract
Parsippany, NJ, Mar 02, 2020 (GLOBE NEWSWIRE via COMTEX) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company's ThyGeNEXT [...]
- Published
- 2020
40. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer.
- Author
-
Chernyshov, P.V., Lallas, A., Tomas‐Aragones, L., Arenbergerova, M., Samimi, M., Manolache, L., Svensson, A., Marron, S.E., Sampogna, F., Spillekom‐vanKoulil, S., Bewley, A., Forsea, A.M., Jemec, G.B., Szepietowski, J.C., Augustin, M., and Finlay, A.Y.
- Subjects
- *
QUALITY of life measurement , *SKIN cancer , *QUALITY of life , *CANCER patients , *META-analysis - Abstract
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer (NMSC) present a review of the literature and position statement on health‐related (HR) QoL assessment in skin cancer patients. A literature search was carried out to identify publications since 1980 that included information about the impact of SC on QoL. Generic, dermatology‐specific, cancer‐specific, SC‐specific, facial SC‐specific, NMSC‐specific, basal cell carcinoma‐specific and melanoma‐specific QoL questionnaires have been used to assess HRQoL in SC patients. HRQoL was assessed in the context of creation and validation of the HRQoL instruments, clinical trials, comparison of QoL in SC and other cancers, other diseases or controls, HRQoL assessment after treatment, comorbidities, behaviour modification, predictors of QoL and survival, supportive care needs, coping strategies and fear of cancer recurrence. The most widely used instruments for HRQoL assessment in SC patients are the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ‐C30), the Functional Assessment of Cancer Therapy‐Melanoma (FACT‐M), Skin Cancer Index (SCI), Short Form 36 Item Health Survey (SF‐36) and the Dermatology Life Quality Index (DLQI). The TFs recommend the use of the cancer‐specific EORTC QLQ‐C30, especially in late stages of disease, and the melanoma‐specific FACT‐M and SC‐specific SCI questionnaires. These instruments have been well validated and used in several studies. Other HRQoL instruments, also with good basic validation, are not currently recommended because the experience of their use is too limited. Dermatology‐specific HRQoL instruments can be used to assess the impact of skin‐related problems in SC. The TFs encourage further studies to validate HRQoL instruments for use in different stages of SC, in order to allow more detailed practical recommendations on HRQoL assessment in SC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
41. Subcategorization of Lung Cancer Based on Tumor Size and Degree of Visceral Pleural Invasion ⁎ [⁎] The main results from this paper were previously published in the Japanese Journal of Lung Cancer, in Japanese [].
- Author
-
Sakakura, Noriaki, Mori, Shoichi, Okuda, Katsuhiro, Fukui, Takayuki, Hatooka, Shunzo, Shinoda, Masayuki, Matsuo, Keitaro, Yatabe, Yasushi, Yokoi, Kohei, and Mitsudomi, Tetsuya
- Subjects
CANCER patients ,LUNG cancer ,MEDICAL care ,ONCOLOGY - Abstract
Background: Lung cancer staging system proposed in 2007 adopts detailed tumor size cut-off values. Alternatively, visceral pleural invasion is deemed an important prognosticator, but has not been easily incorporated into the staging system. Methods: We studied 1,245 patients with resected nonsmall-cell lung cancer. Among patients with current pathologic stage IB (pT2N0M0) disease, those with worse prognosis were reclassified as stage IIA based on tumor size and degree of visceral pleural invasion defined by the Japan Lung Cancer Society: P0 = no pleural involvement beyond elastic layer; P1 = infiltration beyond elastic layer without exposure to pleural surface; and P2 = exposure to pleural surface. Results: The current pT2 category was divided into five groups based on size (≤ 3, > 3 to ≤ 5, and > 5 cm) and degree of visceral pleural invasion (P0-1 or P2). Five-year survival rates in patients with P0-1 tumors greater than 3 cm to 5 cm or less were significantly better (59.5%) than those with tumors greater than 5 cm or P2 tumors (37.5% to 47.3%; p = 0.0014); we defined these two groups as T2a and T2b, respectively, and classified T2aN0M0 as stage IB and T2bN0M0 as stage IIA together with the current T1N1M0. Five-year survival rates for the modified IB and IIA diseases were 70.6% and 60.4%, respectively (p = 0.0414). Conclusions: Modified subcategorization of the pT2 category resulted in T2a (> 3 to ≤ 5 cm and P0-1) and T2b (> 5 cm or P2). Detailed assessment of the degree of visceral pleural invasion could provide more information on tumor characteristics and complement the pathologic staging of lung cancer. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
42. Response to "Letter to the Editor of Radiotherapy and Oncology regarding the paper titled Radiation dose to heart and cardiac substructures and risk of coronary artery disease in early breast cancer patients: A DBCG study based on modern radiation therapy techniques"
- Author
-
Milo, Marie Louise Holm and Offersen, Birgitte Vrou
- Subjects
- *
CORONARY artery disease , *RADIATION doses , *BREAST cancer , *CANCER patients , *ONCOLOGY - Published
- 2023
- Full Text
- View/download PDF
43. Evaluation of quality of life using a tablet PC-based survey in cancer patients treated with radiotherapy: a multi-institutional prospective randomized crossover comparison of paper and tablet PC-based questionnaires (KROG 12-01).
- Author
-
Kim, Haeyoung, Park, Hee, Yoon, Sang, Kim, Tae, Kim, Jinsung, Kang, Min, Jung, Jinhong, Kim, Sang-Won, Yea, Ji, Park, Sung, Park, Young, Park, Hee Chul, Yoon, Sang Min, Kim, Tae Hyun, Kang, Min Kyu, Yea, Ji Woon, Park, Sung Ho, and Park, Young Suk
- Subjects
QUALITY of life ,CANCER patients ,RADIOTHERAPY ,TABLET computers ,FATIGUE (Physiology) ,MENTAL health ,COMPARATIVE studies ,CROSSOVER trials ,INDUSTRIES ,INTERNET ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,STATISTICAL sampling ,TUMORS ,EVALUATION research ,RANDOMIZED controlled trials - Abstract
Purpose: This study compared a tablet PC questionnaire with a paper method for reliability and patient preferences in the acquisition of patient-reported outcomes (PROs) for patients treated with radiotherapy. By comparing the two modes of PRO administration, we aimed to evaluate the adequacy of using tablet PC questionnaires in future clinical use.Methods: Patients were randomized in a crossover study design using two different methods for PRO entry. A group of 89 patients answered a paper questionnaire followed by the tablet PC version, whereas 89 patients in another group completed the tablet PC questionnaire followed by the paper version. Surveys were performed four times per patient throughout the course of the radiotherapy. The Korean versions of the M.D. Anderson Symptom Inventory (MDASI-K) and the Brief Fatigue Inventory (BFI-K) were used. The primary endpoint of our current study was an assessment of patient preference for the survey method. The proportions of patients preferring each mode of questionnaire were evaluated.Results: The proportion of patients who preferred the tablet PC version, paper form, or who had no preference was 52.2, 22.1, and 25.7 %, respectively. More than half of the patients preferred the tablet PC to the paper version in all four surveys. Age, gender, educational status, prior experience of using a tablet PC, and the order of paper to tablet PC administration did not impact patient preferences. Inter-class correlation coefficients (ICCs) between the modes were 0.92 for MDASI-K and 0.94 for BFI-K and ranged from 0.91 to 0.96 on both instruments during the four surveys.Conclusions: A tablet PC-based PRO is an acceptable and reliable method compared with paper-based data collection for Korean patients receiving radiotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
44. Score equivalence of paper-, tablet-, and interactive voice response system-based versions of PROMIS, PRO-CTCAE, and numerical rating scales among cancer patients.
- Author
-
Lee, Minji K., Beebe, Timothy J., Yost, Kathleen J., Eton, David T., Novotny, Paul J., Dueck, Amylou C., Frost, Marlene, and Sloan, Jeff A.
- Subjects
INTERACTIVE voice response (Telecommunication) ,MENTAL health of cancer patients ,TABLET computers ,MENTAL depression ,COMPUTER software ,ACQUISITION of data ,ELECTRODIAGNOSIS ,RESEARCH evaluation ,CONFIDENCE intervals ,RESEARCH methodology evaluation ,RESEARCH methodology ,HEALTH outcome assessment ,AUTOMATIC speech recognition ,CANCER patients ,COMPARATIVE studies ,QUESTIONNAIRES ,RESEARCH funding ,DESCRIPTIVE statistics ,QUALITY of life ,DATA analysis software ,PORTABLE computers ,EVALUATION - Abstract
Background: The study tests the effects of data collection modes on patient responses associated with the multi-item measures such as Patient-Reported Outcomes Measurement System (PROMIS
® ), and single-item measures such as Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and Numerical Rating Scale (NRS) measures. Methods: Adult cancer patients were recruited from five cancer centers and administered measures of anxiety, depression, fatigue, sleep disturbance, pain intensity, pain interference, ability to participate in social roles and activities, global mental and physical health, and physical function. Patients were randomized to complete the measures on paper (595), interactive voice response (IVR, 596) system, or tablet computer (589). We evaluated differential item functioning (DIF) by method of data collection using the R software package, lordif. For constructs that showed no DIF, we concluded equivalence across modes if the equivalence margin, defined as ± 0.20 × pooled SD, completely surrounds 95% confidence intervals (CI's) for difference in mean score. If the 95% CI fell totally outside the equivalence margin, we concluded systematic score difference by modes. If the 95% CI partly overlaps the equivalence margin, we concluded neither equivalence nor difference. Results: For all constructs, no DIF of any kind was found for the three modes. The scores on paper and tablet were more comparable than between IVR and other modes but none of the 95% CI's were completely outside the equivalence margins, in which we established neither equivalence nor difference. Percentages of missing values were comparable for paper and tablet modes. Percentages of missing values were higher for IVR (2.3% to 6.5% depending on measures) compared to paper and tablet modes (0.7% to 3.3% depending on measures and modes), which was attributed to random technical difficulties experienced in some centers. Conclusion: Across all mode comparisons, there were some measures with CI's not completely contained within the margin of small effect. Two visual modes agreed more than visual-auditory pairs. IVR may induce differences in scores unrelated to constructs being measured in comparison with paper and tablet. The users of the surveys should consider using IVR only when paper and computer administration is not feasible. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
45. Recommended Resources for Cancer Patients: Transitioning from Paper Pathfinders to LibGuides.
- Author
-
Prilop, Valerie, Justice, Adela V., and Brackeen, Elizabeth
- Subjects
- *
CANCER patients , *CANCER treatment , *HOSPITAL libraries , *MARKETING , *WEB development , *PATIENT education , *SPECIALTY hospitals - Abstract
In 2015, The Learning Center, a consumer health library at MD Anderson Cancer Center, embarked on a project to translate paper pathfinders into online Recommended Resources in Springshare’s LibGuides platform. This project was successfully undertaken by a small staff of librarians and health education specialists with a range of technical skills and allowed online access to resources available both online and in The Learning Center. This article briefly addresses the activities and decisions leading up to the adoption of LibGuides, outlines the process of creating more than 40 online Recommended Resources, and describes the outcomes to date. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
46. Upgrading the Chemotherapy Consent: Trading in Paper for Tablet.
- Author
-
Wu, Lesley, Smith, Cardinale B., Parra, Jessica, Liu, Mark, Theroux, Haley Hines, and Bhardwaj, Aarti S.
- Subjects
AUDITING ,SPECIALTY hospitals ,PROBLEM solving ,CANCER chemotherapy ,INFORMED consent (Medical law) ,CANCER patients ,CANCER treatment ,HUMAN services programs ,HEALTH care teams ,DESCRIPTIVE statistics ,PATIENT compliance ,MEDICAL needs assessment ,BREAST tumors - Abstract
PURPOSE Our institution participated in the Oncology Care Model, which required us to include many of the 13 elements of the National Academy of Medicine (NAM) care plan into care pathways for our patients. We optimized our existing chemotherapy consent process to meet this need and maximized completion. METHODS Our multidisciplinary committee developed a three-phase Plan-Do-Study-Act process in our breast cancer clinic: (1) update and educate providers on our paper chemotherapy form with multiple components of the NAM care plan including prognosis and treatment effects on quality of life; (2) piloted an electronic chemotherapy consent form to decrease the administrative burden; and (3) autopopulated fields within the electronic consent. We assessed feedback after cycle 1 and created a Pareto chart. The outcome measure was percent completion of chemotherapy consent documents. RESULTS Baseline monthly random chart audit of 40 patients revealed 20% of paper chemotherapy consent forms were completed in their entirety among patients. When we re-educated clinicians about the new paper consent containing the NAM elements, compliance rose to nearly 30%. A Pareto chart confirmed that content redundancy and wordiness were leading to under-completion. After creating and piloting the electronic consent, compliance increased to 90%. Finally, autopopulation with drop-down selections increased and sustained completion to 100%. CONCLUSION Incorporating regulatory requirements into an existing workflow using Plan-Do-Study-Act methodology can reduce administrative burden on clinicians. Additional use of innovative technology can further increase clinician compliance with regulatory requirements while delivering high-value quality care to patients with cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Researchers at Department of Hematology & Oncology Target Venous Thromboembolism (Cancer Screening in Patients with Idiopathic Venous Thromboembolism - a Position Paper of the German Society of Hematology and Oncology Working Group on Hemostasis)
- Subjects
Cancer screening ,Cancer ,Cancer research ,Thromboembolism ,Cancer patients ,Health - Abstract
2015 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Cardiovascular Diseases and Conditions. According to news [...]
- Published
- 2015
48. Free Paper.
- Subjects
- *
BREAST cancer , *CANCER invasiveness , *CANCER cells , *GENE expression , *CANCER patients - Abstract
The article cites a research study that examines the role of MiR- Par3L axis in breast cancer progression. It examined normal tissues and Par3L expressions in breast cancer tissues and cells. Par3L was found to be frequently down-regulated in human breast cancer cells and tissues and Par3L low-expression was associated with aggressive clinicopathological features and poor clinical outcome of breast cancer patients.
- Published
- 2018
- Full Text
- View/download PDF
49. Incorporating Digital Tools to Improve Clinical Trial Infrastructure: A White Paper From the Digital Engagement Committee of SWOG.
- Author
-
Dizon, Don S., Sedrak, Mina, Lewis, Mark A., Cook, Elise, Fisch, Michael J., Klemp, Jennifer R., Sommers, Jonathan, Ciccarella, AnneMarie, Gralow, Julie, Lawton, Wendy, and Nichols, Craig
- Subjects
- *
MEDICAL technology , *CANCER treatment , *CLINICAL trials , *CANCER patients , *INTERNET in medicine - Abstract
Progress toward improvement in cancer therapy relies on clinical trials. Yet, only a minority of eligible patients with cancer enroll as a result of multiple barriers at the patient, investigator, center, and national level. However, the rise of the Internet and mobile technology has created a slew of tools with medical applications, from Web sites to apps to social media platforms, all of which may aide clinicians in our quest to improve the clinical research enterprise. SWOG is one of five members in the National Cancer Institute's National Clinical Trials Network--the nation's oldest and largest publicly funded cancer research network--and is taking a leadership role in exploring and testing the promise of digital engagement through the empaneling of the Digital Engagement Committee. This article outlines the mission, principles, and priorities of the Digital Engagement Committee and proposes how this work may inform the use of digital tools for the cancer research community and, hopefully, translate to improved outcomes for our patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
50. Patient preference: a comparison of electronic patient-completed questionnaires with paper among cancer patients.
- Author
-
Martin, P., Brown, M.C., Espin‐Garcia, O., Cuffe, S., Pringle, D., Mahler, M., Villeneuve, J., Niu, C., Charow, R., Lam, C., Shani, R.M., Hon, H., Otsuka, M., Xu, W., Alibhai, S., Jenkinson, J., and Liu, G.
- Subjects
- *
TUMOR classification , *CANCER patients , *CHI-squared test , *COMPUTERS , *CONFIDENCE intervals , *DEMOGRAPHY , *ETHNIC groups , *LABOR productivity , *MULTIVARIATE analysis , *PATIENT satisfaction , *QUESTIONNAIRES , *RACE , *TECHNOLOGY , *WHITE people , *DATA analysis , *PATIENT selection , *DATA analysis software , *ELECTRONIC health records , *ODDS ratio , *MANN Whitney U Test - Abstract
In this study, we compared cancer patients preference for computerised (tablet/web-based) surveys versus paper. We also assessed whether the understanding of a cancer-related topic, pharmacogenomics is affected by the survey format, and examined differences in demographic and medical characteristics which may affect patient preference and understanding. Three hundred and four cancer patients completed a tablet-administered survey and another 153 patients completed a paper-based survey. Patients who participated in the tablet survey were questioned regarding their preference for survey format administration (paper, tablet and web-based). Understanding was assessed with a 'direct' method, by asking patients to assess their understanding of genetic testing, and with a 'composite' score. Patients preferred administration with tablet (71%) compared with web-based (12%) and paper (17%). Patients <65 years old, non-Caucasians and white-collar professionals significantly preferred the computerised format following multivariate analysis. There was no significant difference in understanding between the paper and tablet survey with direct questioning or composite score. Age (<65 years) and white-collar professionals were associated with increased understanding (both P = 0.03). There was no significant difference in understanding between the tablet and print survey in a multivariate analysis. Patients overwhelmingly preferred computerised surveys and understanding of pharmacogenomics was not affected by survey format. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.